LONDON--(BUSINESS WIRE)--Sengenics, the Functional Proteomics Company, today announced the commercial launch of the Sengenics AxCESS research services suite which features three new KREX-based functional protein arrays developed for higher throughput and cost-effective immuno-proteomics applications. This range of arrays aims to provide greater access to Sengenics’ KREX technology to further facilitate autoantibody characterisation with a focus on autoimmune and cancer research.
“The presence of autoantibodies years before disease onset makes them important potential biomarkers for early diagnosis and better prognosis. However, the field of autoantibody-based immuno-proteomics has been under researched to date and has been restricted by the availability of technologies that have the reproducibility, dynamic range, low limit of detection and low false positive rates required for autoantibody biomarker discovery. With KREX, higher sensitivity and accuracy is achieved due to the production of full-length, correctly folded proteins and our unique surface chemistry. I am delighted that we are now able to make this technology more widely accessible and affordable to researchers who are working towards making impactful contributions in this field,” said Professor Jonathan Blackburn, CSO of Sengenics.
In the last 12 months, Sengenics has made significant discoveries of highly accurate autoantibody biomarker signatures for early diagnosis of Melanoma, Systemic Lupus Erythematosus and illness severity in COVID-19. In addition, the company has filed landmark patents for response prediction in one of the world’s best-selling autoimmune drugs and early diagnosis of Non-small Cell Lung Cancer. Sengenics has also developed the OncoREX p53 cancer array in collaboration with Professor Sir David Lane. Containing over 100 clinically relevant mutant p53 variants, OncoREX can be used for drug discovery as well as autoantibody and antibody screening in cancers.
In conjunction with the launch of AxCESS, Sengenics has made significant investments in scaling up production and operations to provide faster turnaround times and enhanced service offerings.
For more information on the AxCESS research services suite and product range, please visit www.sengenics.com/axcess
Sengenics is a Functional Proteomics company that leverages its patented KREX technology to discover autoantibody biomarker signatures for prediction of drug response and severe immune-related adverse events (irAEs). KREX can also be used to identify autoantibody biomarkers to diagnose cancer, autoimmune, neurodegenerative or infectious diseases with higher sensitivity and specificity than conventional diagnostic tests. Some autoantibodies that are identified as diagnostic biomarkers may be protective and have potential in themselves as therapeutic biomolecules.